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Abstract
A 29-year-old Black female patient was admitted to a psychiatric ward with symptoms of major depressive disorder with psy-
chosis. The patient was started on amitriptyline 50 mg/day and haloperidol 10 mg/day. On day 4 post-admission, the preferred 
first-line antidepressant, fluoxetine, became available and the patient was switched from amitriptyline to fluoxetine 20 mg/
day. On the same day, the dose of haloperidol was reduced to 5 mg/day. Thirteen days post-initiation of these medications the 
patient became talkative, associated with emotional lability, an expansive mood, irritability and restlessness. The working 
diagnosis was changed to bipolar affective disorder in the manic phase. Fluoxetine was discontinued and carbamazepine 600 
mg/day was added to the patient’s treatment regimen. Her manic symptoms started to resolve; however, 14 days post-initiation 
of carbamazepine, the patient had a fever; itchy, discharging eyes; respiratory distress; generalised symmetrical erythema-
tosus rash; buccal ulceration; and conjunctival injection with difficulty opening her eyes. Carbamazepine was immediately 
discontinued and the patient received intravenous fluid resuscitation. The patient recovered considerably after 12 days of 
symptomatic and supportive management, and was transferred back to the psychiatric ward for the continuation of bipolar 
disorder management. Lithium therapy was instituted and the patient was subsequently discharged. Using the Algorithm 
of Drug causality for Epidermal Necrolysis (ALDEN) Stevens–Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) 
drug causality scoring system, carbamazepine and fluoxetine were evaluated as ‘very probable’ and ‘possible’ causes of 
SJS, respectively, in this patient. Fluoxetine-induced SJS was considered on account of previous case reports, however no 
evidence of causality was found in this patient. Consecutive administration with a potential increase in carbamazepine due to 
inhibition of cytochrome P450 (CYP) 3A4 metabolism by fluoxetine was also not ruled out. A diagnosis of carbamazepine-
induced SJS was made and was considered an idiosyncratic adverse drug reaction.
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Key Points 
Stevens–Johnson syndrome (SJS) is one of the most 
severe types of cutaneous adverse reactions to drugs, 
with high morbidity and mortality rates.
Prompt recognition and adequate symptomatic and sup-
portive management of SJS is necessary when prescribing 
known SJS-inducing medications such as carbamazepine.
Careful consideration is needed when prescribing multi-
ple psychotropic drugs with a known risk for causing SJS.
Introduction
Severe cutaneous adverse drug reactions include a serum 
sickness-like reaction, acute generalised exanthematous 
pustulosis (AGEP), drug reaction with eosinophilia and 
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systemic symptoms (DRESS) and epidermal necrolysis 
[1]. Epidermal necrolysis spectrum eruptions such as Ste-
vens–Johnson Syndrome (SJS) and toxic epidermal necroly-
sis (TEN) are considered a continuum and share the same 
pathogenesis. They are only differentiated on the body sur-
face area by epidermal detachment [2]. Epidermal detach-
ment of < 10%, 10–30% and > 30% are designated as SJS, 
SJS/TEN and TEN, respectively [2, 3]. The mortality rate 
ranges from 1 to 5% for SJS, and 25 to 35% for TEN [2].
SJS and TEN are rare severe cutaneous reactions with 
annual incidences of 1.2–6 and 0.4–1.2 per million people, 
respectively [4, 5]. The common cause of SJS/TEN is drug 
exposure, while infections, contrast media, and vaccinations 
are mainly linked to SJS. Drugs commonly associated with 
the development of SJS/TEN include cotrimoxazole, nevi-
rapine, allopurinol, sulfasalazine, phenytoin, phenobarbital, 
lamotrigine, and carbamazepine [1]. The estimated incidence 
of cutaneous adverse drug reactions (CADRs) to psycho-
tropic medications among psychiatric inpatients is 2–5% [6]. 
Lange-Asschenfeldt et al. observed that antiepileptic drug 
(AED) mood stabilizers accounted for the highest CADR rate 
as a drug group, followed by antidepressants, while antip-
sychotics were the least commonly involved medications 
in CADRs [6]. Psychotropics with a high risk of epidermal 
necrolysis are carbamazepine, lamotrigine and phenobarbital 
[3]. Recent studies have also reported on selective seroto-
nin reuptake inhibitor (SSRI)-induced epidermal necrolysis, 
and have implicated fluoxetine, paroxetine, fluvoxamine and 
mirtazapine [7–11]. There is no documentation of epider-
mal necrosis with concurrent administration of an SSRI and 
carbamazepine; therefore, we present a patient with bipolar 
affective disorder who developed SJS following consecutive 
administration of fluoxetine and carbamazepine.
Case Presentation
A 29-year-old Black female patient was admitted to the psy-
chiatric unit with a 2-day history of disorganised behaviour, 
selective mutism, paranoid delusions, and auditory and vis-
ual hallucinations. The patient had been noted to be socially 
withdrawn with a depressive affect and had attempted sui-
cide the day prior to her presentation to the psychiatric unit. 
This was her index psychiatric admission. The patient had 
no significant past medical history and no known drug aller-
gies. An initial diagnosis of major depressive disorder with 
psychosis was made and the patient was started on amitrip-
tyline 50 mg/day and haloperidol 10 mg/day. The patient was 
initially prescribed amitriptyline due to the unavailability 
of fluoxetine at the psychiatric unit at the time of admis-
sion. On day 4, the patient was switched from amitriptyline 
to fluoxetine 20 mg/day and the dose for haloperidol was 
reduced to 5 mg/day.
Thirteen days post-initiation of medications, the patient 
became talkative and had emotional lability and an expan-
sive mood associated with irritability and restlessness. The 
working diagnosis was changed to bipolar affective disorder 
in the manic phase. Fluoxetine was discontinued and carba-
mazepine 600 mg/day was added to her treatment regimen. 
Her manic symptoms started to resolve; however, 14 days 
post-initiation of carbamazepine, the patient had a fever and 
itchy, discharging eyes. On examination she was in minimal 
respiratory distress, with a generalised symmetrical, ery-
thematosus rash more marked on the face, upper limbs and 
chest. Her face was swollen, with bullae noted on her neck 
and chest. In addition, she had an associated buccal ulcera-
tion and conjunctival injection with difficulty opening her 
eyes. Her temperature was 38.2 °C, with  SpO2 of 97%, a 
blood pressure recording of 81/49 mmHg and a regular pulse 
of 108 beats/min. Vesiculobullous lesions were observed 
over the course of the admission, with sloughing of skin, 
especially on the chest and face around the lips.
Routine laboratory assessments showed normal blood 
counts without hypereosinophilia. Hepatic enzyme levels, 
renal function, and serum electrolyte levels were all within 
normal limits, and a serological test was negative for HIV. 
A diagnosis of SJS secondary to carbamazepine exposure 
was made. Evaluation of the SCORE of Toxic Epidermal 
Necrosis (SCORTEN) score on day 1 indicated a score of 
0. No skin biopsy, blood or urine cultures were conducted.
Carbamazepine was immediately discontinued and the 
patient received intravenous fluid resuscitation. She was sub-
sequently transferred to the medical ward where haloperidol 
5 mg/day was maintained and supportive treatment was per-
formed: the patient was kept warm, had careful protection 
of the eroded areas and non-intravenous hydration. Treat-
ment for SJS included a hydrocortisone 100 mg stat dose, 
diazepam 10 mg twice daily, ceftriaxone, tetracycline eye 
ointment, and antiseptic mouth wash. The patient recovered 
completely after 12 days and was transferred back to the 
psychiatric ward, where lithium 500 mg/day was instituted. 
Eighteen days later, the patient was discharged on halop-
eridol 5 mg/day and lithium 500 mg/day; however, she was 
lost to follow-up and we cannot comment further on her 
clinical status.
Discussion
Carbamazepine is a well-known causative agent of drug-
induced SJS among psychotropics [3]. Rare cases of SSRI-
induced epidermal necrolysis, i.e. SJS and TEN, have been 
described in the literature [7–11]. To our knowledge, no 
cases of epidermal necrolysis have been described with 
coadministration of carbamazepine and an SSRI. In the case 
presented, the patient had been taking carbamazepine for 
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14 days after discontinuing fluoxetine. The temporal rela-
tionship between the development of SJS after the addition 
of carbamazepine suggests that carbamazepine was the caus-
ative agent. Although the median latency period (interquar-
tile range) for the development of SJS with carbamazepine 
is 15 days (12–20) [12], latency periods of 4 weeks have also 
been reported [13]. The latency period for SSRI-induced 
SJS is 1–3 weeks. Using the Algorithm of Drug causality 
for Epidermal Necrolysis (ALDEN) scoring system for SJS/
TEN, carbamazepine scored +6 and fluoxetine scored +2. 
Therefore, carbamazepine and fluoxetine were considered 
‘very probable’ and ‘possible’ causes of SJS, respectively, 
in our patient [14].
Carbamazepine-induced SJS has long been thought 
of as an idiosyncratic, dose independent, unpredictable 
adverse event specific to an individual [15]; however, 
current evidence indicates that carbamazepine-induced 
SJS/TEN is a predictable, specific, delayed hypersensi-
tivity immune reaction involving human leukocyte anti-
gen (HLA) alleles specific for carbamazepine and other 
drugs in defined populations [16]. HLA-B*15:02 and 
HLA-B*31:01 have been associated with carbamazepine-
induced SJS in Asian (Han Chinese, Thai, Indian and 
Malaysian) and Caucasian (and Japanese) populations, 
respectively [17–19]. Recent evidence suggests this pos-
sibility, as shown by the phenytoin and nevirapine-induced 
SJS/TEN associated with reduced drug clearance due to 
metaboliser enzyme polymorphisms [20, 21]. However, 
we were not able to genotype our patient for HLA alleles, 
therefore we cannot confirm the involvement of the pheno-
type-specific characteristics of the patient that might have 
contributed to the development of SJS. Although associa-
tion with specific HLA genotypes may be necessary, it is 
not sufficient for the development of SJS/TEN [18]. Other 
factors such as the individual variation in drug metabolism 
or clearance, HIV-1 seropositivity, polypharmacy, and 
competitive drug inhibition may also play an important 
role in SJS/TEN development with carbamazepine [1, 18, 
22, 23].
It has been postulated that no biologic effect is dose-
independent [24] and that immune-mediated reactions 
only occur when a critical dose threshold has been reached 
[15, 25]. The maximum incidence for idiosyncratic reac-
tions is often at a dose below the therapeutic range and 
remains constant within the therapeutic range [24]; how-
ever, this biologic dose-dependency principle (and pos-
sibly immune tolerance) is used successfully in desensi-
tisation protocols for the safe introduction of medicines 
known to have idiosyncratic reactions [15, 24, 25]. Given 
the current understanding of idiosyncratic reactions, a 
potential increase in carbamazepine plasma concentration 
due to CYP3A4 inhibition by fluoxetine and norfluoxetine 
may have reached the threshold for the immune-mediated 
carbamazepine-induced SJS in our patient, leading to the 
observed adverse reaction [25, 26]. Increases in plasma 
carbamazepine or its metabolites increases the likelihood 
of adverse events, and possibly SJS, as occurs with phe-
nytoin [27, 28]. It is possible that prior administration 
with fluoxetine may have increased the risk for SJS in our 
patient. The inhibitory capacity on CYP3A4 substrate 
clearance can persist up to 3 weeks post administration of 
fluoxetine due to the long half-life of norfluoxetine [29]. In 
our patient, carbamazepine was administered 14 days after 
fluoxetine was discontinued; however, we were unable to 
measure plasma concentrations of carbamazepine to con-
firm that competitive inhibition of metabolic enzymes by 
fluoxetine or norfluoxetine was involved in the develop-
ment of SJS in our patient. Therefore, we cannot conclude 
that prior administration of fluoxetine may have increased 
the risk of carbamazepine-induced SJS.
Although epidermal necrolysis is rare with the use of 
SSRIs, several case reports have been documented for 
SJS or TEN with mirtazapine, fluoxetine, fluvoxamine 
and paroxetine [6–10]. Many of the reported cases have 
occurred in female patients who had received an SSRI 
for a duration ranging from 3 to 14 days. In our case, the 
patient had discontinued fluoxetine for 14 days when she 
developed SJS. However, fluoxetine and its major metabo-
lite norfluoxetine have long elimination half-lives of 1–4 
days and 7–15 days, respectively [30]. Although it is pos-
sible that fluoxetine or its metabolite norfluoxetine was 
involved in the development of SJS in our patient, it is 
more likely that the SJS was caused by carbamazepine and 
not by fluoxetine.
Conclusions
Carbamazepine-induced SJS is an idiosyncratic reaction; 
however, current evidence suggests that HLA genetic pre-
disposition, drug structure, the patient’s metabolic charac-
teristics and T cell clonotypes need to be aligned for SJS to 
occur [18, 27]. More research is needed in African popu-
lations to delineate the pharmacogenomic risk alleles and 
to then provide relevant pre-prescription pharmacogenetic 
tests, as happens with people of Asian ancestry [19]. Clini-
cians should be aware of cutaneous adverse reactions due 
to psychotropic medications, particularly with AED mood 
stabilizers.
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